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Abstract 
 
Background  
Gestational diabetes mellitus (GDM) is defined as an alteration of the glucose metabolism 
during pregnancy. GDM is a common pregnancy complication affecting over 17% of all 
pregnancies and is associated with maternal and neonatal morbidity. Universal screening is 
widely the norm. 
 
Objective 
 
The present study was performed to investigate the impact of the presence- or lack - of risk 
factors on maternal outcomes in pregnancies complicated with GDM, during pregnancy and 
after delivery. We investigated this in the context of a regular care including capillary glucose 
management, lifestyle modification, treatment if indicated, which may impact some of the 
outcomes.  
 
Material and methods 
 
This study included 673 pregnant women diagnosed with GDM according to the International 
Society of Diabetes in Pregnancy Study Group (IADSPG) criteria with a 75g oral glucose 
tolerance test (OGTT) performed at 24-28 weeks of gestational age.  
Anthropometric and metabolic characteristics were assessed for each participant. Risk factors 
were chosen based on the recommendation of the American Diabetes Association (ADA), their 
known impact on the risk of GDM, their prevalence and the feasibility to define them clearly 
in routine clinical care. These included: previous GDM, first degree relatives with type 2 
diabetes mellitus (T2DM), ethnicity with high diabetes prevalence, overweight and/or obesity. 
The presence of maternal, mostly metabolic outcomes such as the need for any medical 
glucose treatment (regardless if insulin or metformin), HbA1c level, FBG and 2h BG values 
after the 75g OGTT 6-8 weeks post-partum as well as the mode of delivery were prospectively 
recorded according to these individual risk factors as well as according to the presence or 
absence of any risk factor. We tested for normal distribution for continuous variables. Logistic 
regression and linear regression were used to compare dichotomous variables and continuous 
variables respectively. Outcomes are expressed as odds ratio and β coefficient. The latter, if 
statistically significant, means that for every 1-unit increase in the predictive factor, the 
outcome variable will increase by the β coefficient value.  
 
Results 
 
The mean age was 32.9 (± 5.4). Women with a previous history of GDM had significantly higher 
values of HbA1c at the first GDM appointment (β coefficient 0.22 [0.11-0.33]), at the end of 
pregnancy (β coefficient 0.17 [-0.2-0.36]), and at 6-8 weeks post-partum (β coefficient 0.18 
[0.08-0.28]). Same was found for fasting blood glucose (FBG) (β coefficient 0.26 [0.10-0.42]), 
2h-BG (β coefficient 0.89 [0.42-1.36]) levels during the OGTT at 6-8 weeks post-partum. The 
need for medical glucose treatment was greater in women with this RF (OR 1.97 [1.07-3.06]).  
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Women with history of first-degree relatives with T2DM had significantly higher values of 
HbA1c at the first GDM appointment (β coefficient 0.11 [0.05-0.18]), at the end of pregnancy 
(β coefficient 0.16 [0.06-0.27]) as well as 2h-BG (β coefficient 0.34 [0.05-0.62]) levels post-
partum. The need to treat was greater in women with the RF (OR 1.52 [1.08-2.14]). 
Women with a high-risk non-Caucasian ethnicity had higher values of HbA1c at the first GDM 
appointment (β coefficient 0.09 [0.32-0.17]) and at 6-8 weeks post-partum (β coefficient 0.11 
[0.04-0.17]). The same was found for post-partum FBG (β coefficient 0.13 [0.01-0.22]), and 2h-
BG (β coefficient 0.45 [0.17-0.72]) levels. Women with this RF were more likely to need 
medical glucose treatment (OR 1.51 [1.08-2.14]). 
Overweight and/or obese women had significantly higher values of HbA1c at the first GDM 
appointment (β coefficient 0.15 [0.09-0.21]) and at 6-8 weeks post-partum (β coefficient 0.09 
[0.04-0.15]). The same was found for FBG (β coefficient 0.27 [0.18-0.36]), 2h-BG (β coefficient 
0.33 [0.06-0.59]) levels during the OGTT at 6-8 weeks post-partum. The need for medical 
glucose-lowering treatment was greater in women with this RF (OR 1.74 [1.26-2.40]). 
Obese women had significantly higher values of HbA1c at the first GDM appointment (β 
coefficient 0.15 [0.07-0.22]), at the end of pregnancy (β coefficient 0.15 [0.01-0.25]), and at 6-
8 weeks post-partum (β coefficient 0.11 [0.04-0.18]). The same was found for FBG (β 
coefficient 0.17 [0.07-0.28]) levels during the OGTT at 6-8 weeks post-partum. The need for 
medical glucose treatment was greater in women with this RF (OR 1.67 [1.12-2.48]). 
Women with at least one risk factor had more likely elevated HbA1c level at the first GDM 
consultation (β coefficient 0.14 [0.07-0.21]), at the end of pregnancy (β coefficient 0.11 [0.01-
0.22]) and at 6-8-week post-partum (β coefficient 0.11 [0.04-0.17]). Similar increase was found 
for fasting, 1 and 2h-BG. Women with a risk factor were more frequently treated 
pharmacologically. 
 
Conclusion 
 
Women with an history of GDM and with first degree relative with type 2 diabetes mellitus 
and women of high-risk ethnicity and overweight/obese women have more frequent adverse 
pregnancy and maternal metabolic outcomes during and after pregnancy. Surprisingly none 
of these risk factors are associated with an increase of caesarean delivery in pregnancies 
complicated with GDM in the setting of routine clinical care and few are associated with a 
difference of metabolic control at the end of pregnancy.   
 
Keywords: gestational diabetes mellitus, predictive factors, risk factors, maternal outcome. 
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Introduction  
 
Gestational diabetes mellitus (GDM) is defined as “glucose intolerance with onset or first 
recognition during pregnancy that does not qualify for diabetes” (1). It is one of the most 
frequent complication of pregnancy (2). It is associated with adverse health outcomes for the 
mother and the child (3). Although GDM is limited to pregnancy, and usually disappears after 
the delivery, the short-term and long-term consequence have medical repercussions. For the 
offspring, adverse outcomes range from macrosomia, shoulder dystocia, neonatal 
hypoglycaemia and respiratory distress. Other studies have also shown an increased risk of 
overweight and the metabolic syndrome in adult offspring of women with GDM (4)-(5). For 
the mother, this is related to more pregnancy complications, including preeclampsia, higher 
rates of cesarean section and an increased risk of glucose intolerance postpartum. Moreover, 
women affected by GDM have 40% higher life-time risk of developing cardiovascular disease 
(CVD) and type 2 diabetes (T2DM)(6). 
 
GDM is a growing public health concern. The prevalence is rapidly increasing, concomitant to 
rising rates of obesity, inactivity, older maternal age, and changing diagnostic criteria (7). The 
prevalence is estimated between 7% and 17% (8). These estimations depend on the 
population studied, screening methods and diagnostic criteria selected. In Switzerland, the 
prevalence has been found to be 10.9% (9). The perinatal period is a key moment to intervene 
to improve the metabolic health. The goal in management of women with GDM is to improve 
short- and long-term health outcomes for both the mother and the child.  
GDM screening and diagnosis has been a subject of debate for decades with conflicting 
recommendation for universal and selective screening among expert groups. The initial 
landmark study and cornerstone for diagnostic criteria of GDM was O’Sullivan and Mahan’s 
paper in 1964 (10). Simultaneously to technical advances and scientific research, these criteria 
have gone through various changes in recent decades. A significant milestone was the 
Hyperglycaemia and Adverse Pregnancy Outcome (HAPO), a multicentric and prospective 
study in 2008, designed to investigate the associations of maternal glycemia with risks of 
adverse pregnancy outcome (11). HAPO study and therefore pave the way for new diagnostic 
criteria (12). The aim and subsequently the challenge, was defining a pathologic threshold for 
maternal glycemia values. It consolidated the already known linear association between 
maternal glycemia and adverse foeto-maternal outcomes. Based on the HAPO study findings, 
expert opinion and cost-effectiveness, the International Society of Diabetes in Pregnancy 
Study Group (IADPSG) established new diagnostic cut-off, consequently reaching an 
international consensus (13). Since then, the IADPSG criteria have been endorsed by WHO 
(World Health Organisation), FIGO (International Federation of Gynaecology and Obstetrics), 
the American Diabetes Association (ADA), and several other national diabetes societies. 
Commonly GDM is now diagnosed by glucose testing with a 75-g Oral Glucose Tolerance Test 
(OGTT) at 24–28 weeks of gestation in all pregnancies not already diagnosed with overt 
diabetes or GDM. “Universal screening” was introduced in 2011 in Switzerland the decision is 
driven by local resources and health care priorities.  
GDM is multifactorial disease and, risk factors (RF) are the same as for T2DM (14). The ADA 
lists overweight (BMI ≥ 25 kg/m2), first-degree relative with diabetes, high-risk race/ethnicity 
(e.g., African American, Latino, Native American, Asian American, Pacific Islander), women 
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diagnosed with a previous history of GDM. Other risk factors are listed in the ADA, which we 
did not include, namely, hypertension (≥ 140/90 mmHg or on therapy for hypertension), 
dyslipidaemia, women with polycystic ovary syndrome (PCOS), physical inactivity.  
The present study was performed to investigate the impact of the presence - or lack - of risk 
factors on maternal outcomes in pregnancies complicated with GDM, during pregnancy and 
after delivery. We investigate this in the context of a regular care, including capillary glucose 
management, lifestyle modification, treatment if indicated which may impact on some of the 
outcomes.  
 
Materials and methods  
 
Literature  
 
Exploring scientific literature was the first step in this study. The purpose was to assess the 
current knowledge/status on the subject. The search engine used was mainly PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed) and Google (http://www.google.ch) using several 
terms such as “gestational diabetes, GDM risk factors, GDM outcomes, American diabetes 
association (ADA), diagnostic criteria”. Up to date database (http://www.uptodate.com) was 
an important source to keep up with current knowledge on the topic. In this study, we decided 
to base ourselves on the “American Diabetes Association Standards of Medical Care in 
Diabetes 2017” which are similar as the risk factors in the 2019 edition. Pregnant women 
diagnosed with GDM were analysed based on risk factors from the ADA 2017 guidelines (BMI 
above 25 kg/m2, previous GDM, family history of type 2 diabetes mellitus and ethnic family 
origin with a high prevalence of diabetes). Risk factors were chosen based on the 
recommendation of the ADA, their known impact on the risk of GDM, their prevalence and 
the feasibility to define them clearly in routine clinical care. Thus, we did not include 
hypertension, dyslipidaemia, history of CVD, physical inactivity and the presence of PCOS or 
known prediabetes 
Additionally, to these four risk factors, we included “BMI above 30 kg/m2” that was a risk factor 
mentioned by the “National Institute for Care Excellence (NICE) 2016”(15).   
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Tableau 1 Comparison of risk factor for GDM  
NICE  ADA 
*Previous gestational diabetes  *Women who were diagnosed with GDM in a 
previous pregnancy 
*Family history of diabetes 
(first-degree relative with diabetes) 
*First-degree relative with diabetes 
Minority ethnic family origin with a high 
prevalence of diabetes 
*Members of a high-risk ethnic population 
(e.g., African American, Latino, Native 
American, Asian American, Pacific Islander) 
*Obesity (BMI >30kg/m2) *Overweight or obesity (BMI ≥ 25 kg/m2 or ≥ 23 
kg/m2 in Asian Americans**) 
Previous macrosomic baby 
weighing ≥ 4.5 kg 
Physical inactivity 
 Hypertension (≥140/90 mmHg or on 
therapy for hypertension) 
 
 HDL cholesterol level ,35 mg/dL (0.90 mmol/L) 
and/or a triglyceride level .250 mg/dL 
(2.82 mmol/L) 
 Women with polycystic ovary syndrome 
 A1C ≥5.7%, IGT, or IFG on previous testing 
 Other clinical conditions associated with 
insulin resistance (e.g. obesity, 
acanthosis nigricans) 
 History of CVD 
*Assessed risk factors. ** Not taken into account.  
 
Study population design and setting  
 
The study group consisted of parous women from the endocrinologic and metabolic 
department at the Centre Hospitalier Universitaire Vaudois (CHUV). This prospective study 
collected data of 949 pregnant women followed in the endocrinologic and metabolic 
department at the CHUV between June 2011 and December 2017. The list of participants was 
obtained through the local database of GDM unit. Medical and clinical data were collected 
through Soarian, the GDM medical chart and reports of medical and para-medical 
appointments. The data collected was entered in Secutrial. For each patient age, age of 
gestation, body mass index (BMI) and weight before pregnancy, weight at the first medical 
appointment, gravidity, parity, history of GDM, first degree relative with T2DM and ethnicity 
was assessed. Patients gave their voluntary and informed consent. Parous women who didn’t 
give consent (n=114), who were enrolled in an randomised controlled trial (n=21), with normal 
OGTT results (n=7), pre-existing type T1DM (n=17) and T2DM (n=23), pre-existing glucose 
intolerance (n=15), patients with 24-28-week 75g OGTT values indicating a pre-existing 
diabetes (n=24), women with normal OGTT results (n=7) and lost to follow up (n= 44) were 
excluded. Moreover, women with undocumented BMI before pregnancy (n=11) were 
excluded. In total, we excluded 276 women. The final sample included 673 pregnant women.  
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Screening and GDM diagnostic    
 
The protocol validated in CHUV to diagnose GDM supports the IADPSG position on universal 
one-step screening. The protocol is based on the ADA 2017 and the IADPSG Consensus Panel 
2010 recommendations. All parous women not previously diagnosed with overt diabetes or 
GDM undergo a 75g oral glucose tolerance test (OGTT), with a fasting, 1h and 2h plasma 
glucose measurement between the 24-28th weeks of gestation.  
According to the IADPSG criteria, GDM is confirmed when:  
- fasting blood glucose (FBG) ≥ 5.1mmol  
- and/or 1h blood glucose ≥ 10.0 mmol/l  
- and/or 2h blood glucose ≥ 8.5 mmol/l (16). 
Note that one pathological value is enough to diagnose an onset of GDM. As aforementioned 
the risk factor selected are the following: BMI above 25 kg/m2, BMI above 30 kg/m2, previous 
GDM, family history of type 2 diabetes mellitus and ethnic family origin with a high prevalence 
of diabetes. These specific RF were selected for their predictive importance and high 
frequency in women with GDM, as well as the feasibility to define them clearly in routine 
clinical care (17)-18-19). 
  
Usual clinical care  
 
Prepartum management  
 
Parous women with an abnormal 75g OGTT between 24-28 week of gestation are referred by 
the Maternity of the CHUV or their obstetrician/gynaecologist (OB/GYN) for expert care 
management. The diabetology unit in CHUV is interdisciplinary health-care team, composed 
of diabetic nurse educators, dietitians, physicians and physiotherapists with expertise in 
diabetes.  
At first clinical appointment the patients were received by a nurse or a physician for an 
assessment. Pregnant women underwent a medical history taking, a physical and biological 
examination. During this encounter, attention was also placed on informing and educating the 
patients on the topic of GDM, importance of diet and physical activity. The women are also 
trained how to self-monitor blood glucose (SMBG). The women are instructed to self-monitor 
4x/day, fasting and 2h after each meal to improve pregnancy outcomes (16). Similar blood 
glucose targets are recommended national and international societies. Targets for self-
monitored glucose control during pregnancy, as recommended by the Société Suisse 
d'Endocrinologie et de Diabétologie (SSED) 2009, Prise de position Gynécologues et 
Diabétologue Suisse 2011 and IADPSG 2010 are the following:  
- FBG ≤ 5.3 mmol/L 
- 1h postprandial ≤ 8 mmol/L 
- 2h postprandial ≤ 7 mmol/L 
In addition, patients see a dietician experienced in caring for women with diabetes at least 
once during pregnancy. They receive practical nutrition education and personalised 
recommendations about their condition and weight gain during pregnancy (20).  
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They are also actively encouraged to regularly exercise; thus, all participants were offered the 
possibility to see a physiotherapist to increase their physical activity. The first-line treatment 
is lifestyle modification through dietary therapy and physical activity.  
If despite these measures ≥ 2 blood glucose values are above normoglycemic threshold (FBG 
≤ 5.3 mmol/L and/or 2h postprandial ≤ 7 mmol/L) a medical glucose-lowering treatment is 
initiated.  
 According to the glucose values and the patient’s preferences, insulin is most often the first-
line drug for women with GDM after failing to achieve glucose control with lifestyle changes. 
Insulin type and dose regimens are individualised. Rapid-acting and long-acting insulin are 
usually combined, therefore mirroring physiologic insulin secretion. Metformin is an 
alternative. 
Finally, according to the metabolic control and the need for medical treatment, labour can be 
induced between 38-40 weeks’ gestation to reduce risk of still birth and caesarean section 
(21). Any medical glucose-lowering treatment is stopped at delivery. 
 
Post-partum glucose management 
 
Mothers are encouraged to breastfeed immediately after delivery and ideally at least up to 6 
months post-partum in prevention of metabolic syndrome and type 2 diabetes in the 
mother(22). In CHUV  6-8 weeks’ post-partum a 75g OGTT FBG and 2h BG was repeated along 
with Hb1Ac to identify women with metabolic risk such as prediabetes (impaired fasting 
glucose (IFG) and/or impaired glucose tolerance (IGT)) as recommended by the ADA and NICE 
(2015) (see table 2).  
 
Tableau 2. Diagnostic criteria for IGT and diabetes according to ADA (2017) and NICE (2015) 
 Normoglycemia Prediabetes  Diabetes  
FBG  < 5.6  5.6-6.9 (IFG) ≥7.0 
2h post-prandial, mmol/L <7.8 7.8-11 (IGT) ≥11.1 
HbA1c, % <5.7 5.7-6.4 ≥6.5 
 
Risk factor and outcome measurements  
 
For each participant, biological and clinical parameters were assessed at the first medical 
appointment. Descriptive variables included age, gestational age, weight and BMI before 
pregnancy, gravidity and parity, previous pregnancy, Hb1aC, first degree relative with T2DM, 
and ethnicity. Predictor variable, derived from the ADA 2017 modified with NICE 2015, 
analysed are:  
- previous GDM  
- first degree relatives with T2DM  
- ethnicity with high diabetes prevalence (Native American, African and African 
descendant, Latino, Asian American, Pacific Islander) 
- overweight and/or obese women based on BMI in comparison to underweight and/or 
normal weight (ADA, 2017) 
11 
 
- obese women based on BMI in comparison to underweight and/or normal weight 
and/or overweight women (NICE, 2015) 
 
Outcomes were chosen based on their increased prevalence and the feasibility to define them 
precisely during routine care. We were specifically interested in maternal outcomes and in 
metabolic health outcomes. Maternal outcomes accounted for were the need for medical 
glucose-lowering treatment and the mode of delivery. Metabolic maternal outcome in 
pregnancy included, both HbA1c value at first GDM visit and at the end of pregnancy. 
Metabolic maternal outcomes after pregnancy included:  HbA1c level, FBG and 2h BG values 
after the 75g OGTT, all measured 6-8 weeks post-partum. 
 
Statistical analysis 
 
Descriptive statistics included means and standard deviation (SD) for normal continuous 
variables, numbers and percentages for categorical variables. The normality was verified by 
the observation of histograms. Logistic regression was used to compare dichotomous 
variables. Outcome data are presented as odds ratios with 95% confidence intervals, 
comparing GDM risk factors. Linear regression was used to compare continuous variable. 
Outcome data is expressed as coefficient beta with 95% confidence intervals. A significative 
p-value was set to p<0.05. Data analysis was performed using Stata (Release 15. College 
Station, TX: StataCorp LLC) statistical software.  
To examine the impact predictive factors on pregnancy and maternal outcomes, participants 
were divided in two groups for each risk factor assessed. On one hand women with the risk 
factor and on the other women without the risk factor in question. Note that patients with 
undocumented and missing data are considered risk free, as clinicians must report risk factor 
in history taking. 
 
Results  
 
Patients’ characteristics at the first consultation are shown in Table 3a. A total of 946 women 
were identified. We analysed date from 673 women diagnosed with GDM. Their mean age 
was 32.9 ± 5.4 [range 18-54] years. The first visit was on average at 28.5 ± 3.5 week of 
gestation. The average BMI before pregnancy was 26.1 kg/m2, with half of the women being 
“underweight and normal weight”, 28 % were “overweight” defined as BMI ≥25 and <30 kg/m2 
and 22% of the women were considered “obese” (BMI ≥ 30 kg/m2). Note no adjustment was 
made for Asian, the ADA and several studies have recommended lowering BMI cut point for 
overweight to 23 kg/m2(23). The distribution of parity was normal. The mean parity was 
primipara, with an average of about 2.6 gravida.  
The sample was heterogenous population in terms of origins. The sample population consisted 
of 404 Caucasians including 201 Swiss patients. Among the 243 high-risk population we 
identified 110 Africans, 95 Asians, 34 south Americans, 2 central Americans and 2 Pacific 
islanders. 26 were missing or undocumented and filed as “low-risk ethnicity”. 
 
  
12 
 
Table 3a. Descriptive characteristics at baseline 
Characteristics n Mean (SD) or N (%) 
Weeks of gestation  671 28.5 (3.5) 
Age, years  673 32.9 (5.4) 
BMI before pregnancy, kg/m2 673 26.1 (5.4) 
    Underweight and normal weight, 
% 
338 50.2  
     Overweight, % 187 27.8 
     Obesity, % 148 22 
Weight before pregnancy, kg  661 70.2 (16.1) 
Gravidity 673 2.54 (1.6) 
Parity 386 1.64 (0.9) 
GDM in previous pregnancy, yes/no  420 63/357,  
(15.0/85.0) 
First grade family history of T2DM, 
yes/nob 
673 218/455 
(32.4/67.6) 
High-risk ethnicity, yes/no  673 243/430 
(36.1/63.9) 
Weight at RDV1e, kg 645 80.6 (16.2) 
HbA1c at RDV1e, % 634 5.5 (0.4) 
SD indicates standard deviation 
a. underweight <18.5 kg/m2, normal range 18.5-24.99 kg/m2, overweight ≥25-30 kg/m2, obesity ≥30 kg/m2 
b. “no” includes no history of GDM. The “undocumented” answers were assumed as “no” as clinicians must check 
the presence of this risk factor 
c. 1st degree relatives include, mother, father, sister, brother, daughter, son. The “undocumented” answers were 
assumed as “no” as clinicians must check the presence of this risk factor  
d. high-risk ethnicity denotes nationality from the following areas in the world: Africa, Central America, South 
America, East Asia, West Asia, Oceania. “No” means low risk ethnicity such as North America, East Europe, West 
Europe (incl. Switzerland). Undocumented answers were not included.  
e. denotes first GDM visit 
 
Table 3b. Descriptive characteristics at follow-up 
 n Mean (SD) or N (%) 
Need for treatmenta, yes/no 673 349/324  
(51.9/48.1) 
Mode of deliveryb 654 266/388 
(40.7/59.3) 
HbA1c end of pregnancyc 236 5.6 (0.4) 
HbA1c ppd 612 5.4 (0.4) 
FBG ppd  611 5.1 (0.6) 
2h BG ppd  604 5.6 (1.7) 
SD indicates standard deviation, pp denotes postpartum   
a. refers to the need to pharmacologically treat GDM. “Yes” includes all following drugs: metformin, insulin or 
combination of both.  
b. includes childbirth by vaginal delivery, undocumented or missing data are not included 
c. refers to HbA1c measured at the end of pregnancy  
d. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
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Pregnancy outcomes and descriptive characteristics during follow-up are presented in Table 
3b.  
In the study population, about 52% were pharmacologically treated which included, fast-
acting insulin, long-acting insulin and/or metformin. Forty-eight percent were solely treated 
with lifestyle modification, including nutritional adaptation and physical activity.  
Considering the ADA risk factors assessed, twenty-three percent (n=156) of the women 
diagnosed with GDM had zero risk factor. All in all, seventy-seven percent (n=517) of the 
pregnant women with GDM had at least one of the risk factors studied.  
When the NICE guidelines were applied, thirty-two percent of women (n=215) with GDM had 
zero of the assessed risk factors. Sixty-eight percent of women (n=458) with GDM had at least 
one of the risk factors analysed. 
 
Pregnancy and maternal adverse metabolic outcomes regarding previous GDM as a predictive 
factor are reported in Table 4.  
HbA1c values were higher at first GDM visit in the group with personal GDM history, but not 
at the end of pregnancy. Pharmacologic treatment is also initiated significantly more 
frequently in this group. 
 
Table 4. GDM history as a predictor factor 
Outcome  Women without 
previous GDM  
(n=610) 
Women with 
previous GDM 
(n=63) 
β (95 % CI) or  
OR* (95% CI) 
p-value 
HbA1c RDV1a  
Mean (SD) 
5.45 (0.40) 5.67 (0.49) 0.22 (0.11-0.33) <0.0001 
HbA1c end of 
pregnancyb 
Mean (SD) 
5.55 (0.39) 5.72 (0.42) 0.17 (-0.20-0.36) 0.072 
Need for treatment, 
yes/no, N (%)  
309/244 
(55.90/44.10) 
40/16 
(71.43/28.57) 
1.97* (1.08-3.06) 0.027 
Caesarean vs vaginal 
N (%)  
200/276 
(42.02/57.98) 
20/27  
(42.55/57.45) 
1.02* (0.56-1.87) 0.943 
HbA1c ppc 
Mean (SD) 
5.37 (0.37) 5.55 (0.39) 0.18 (0.08-0.28) 0.001 
FBG ppc 
Mean (SD)  
5.00 (0.54) 5.26 (0.74) 0.26 (0.10-0.42) 0.001 
2h BG ppc 
Mean (SD) 
5.53 (1.59) 6.42 (2.27) 0.89 (0.42-1.36) <0.0001 
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
There is no difference in the rate of caesarean sections. However, HbA1c and 75g OGTT values 
(FBG, 2h- BG) were significantly higher in the group of “women with previous GDM”.  
 
Pregnancy and maternal adverse metabolic outcomes regarding first degree relative with 
T2DM as a predictive factor are reported in Table 5. 
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HbA1c levels during pregnancy are significantly higher in the group with a positive family 
history for T2DM than in the group without, both at the first GDM visit and at the end of 
pregnancy. These women also present a 52% more frequent need to treat. 
 
There is no difference in the rate of caesarean section. The women with first degree relatives 
with T2DM have higher values in post-partum 2h BG 75g OGTT.  
 
Table 5. First degree relative with T2DM as a predictor factor 
Outcome  No first degree 
relative with DM2  
(n=455) 
First degree 
relative with 
DM2 (n=218)  
Beta (95 % CI) or  
OR* (95% CI) 
p-
value 
HbA1c RDV1a 
Mean (SD)  
5.34 (0.39) 5.55 (0.42) 0.11 (0.05-0.18) 0.001 
HbA1c end of 
pregnancyb 
Mean (SD) 
5.50 (0.35) 5.66 (0.45) 0.16 (0.06-0.27) 0.002 
Need for treatment, 
yes/no, N (%)  
216/185 
(53.87/46.13) 
133/75 
(63.94/36.06) 
1.52* (1.08-2.14) 0.017 
Cesarean vs vaginal 
N (%)  
153/210 
(57.8/42.2) 
67/93 
(41.9/58.1) 
0.99* (0.68-1.44) 0.953 
HbA1c ppc 
Mean (SD) 
5.38 (0.37) 5.42 (0.38) 0.04 (-0.2-0.10 0.196 
FBG ppc 
Mean (SD)  
5.01 (0.58) 5.06 (0.53) 0.05 (-0.04 -0.15) 0.287 
2h BG ppc  
Mean (SD) 
5.49 (1.64) 5.83 (1.75) 0.34 (0.05-0.62) 0.019 
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
Pregnancy and maternal adverse metabolic outcomes regarding high-risk ethnicity as a 
predictive factor are reported in Table 6. The pregnant women in the high-risk ethnicity had 
higher HbA1c levels at first GDM visit, but not at the end of pregnancy. The need to treat 
considerably higher in women in this high-risk ethnicity group.  
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Table 6. High risk ethnicity as a predictor factor 
Outcome  Low-risk  
ethnicity1  
(n=430) 
High-risk 
ethnicity2 
(n=243) 
Beta (95 % CI) or  
OR* (95% CI) 
p-
value 
HbA1c RDV1a 
Mean (SD)  
5.44 (0.41) 5.52 (0.40) 0.09 (0.32-0.17) 0.004 
HbA1c end of pregnancy  
Mean (SD)b 
5.54 (0.40) 5.61 (0.39) 0.084 (-0.03-0.19) 0.143 
Need for treatment, 
yes/no, N (%) 
210/174 
(54.7/45.3) 
153/93 
(62.1/37.9) 
1.51* (1.08-2.14) 0.017 
Cesarean vs vaginal 
N (%)  
130/196 
(39.8/60.2) 
98/122 
(44.55/55.45) 
1.24* (0.87-1.79) 0.231 
HbA1c ppc 
Mean (SD) 
5.35 (0.37) 5.44 (0.38) 0.11 (0.04-0.17) 0.001 
FBG ppc 
Mean (SD)  
4.98 (0.49) 5.09 (0.64) 0.13 (0.03-0.22) 0.007 
2h BG ppc  
Mean (SD) 
5.45 (1.59) 5.87 (1.84) 0.45 (0.17-0.72) 0.001 
1. “low risk ethnicity” comprises north Americans, east and west Europeans 
2. “high risk group” denotes nationalities from Africa, central America, south America, east Asia, west Asia and 
Oceania 
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
There is no difference in the rate of caesarean sections. The women with high-risk ethnicity 
have higher postpartum HbA1c and 75g OGTT (FBG and 2h BG) values. 
 
Pregnancy and maternal adverse metabolic outcomes regarding overweight/obesity as a 
predictive factor are reported in Table 7.  
HbA1c values at the first GDM visit, but not at the end of pregnancy, were significantly higher 
in the group of overweight/obese women than in the normal-weight counterparts. Likewise, 
pharmacologic treatment is 74% significantly more frequent in this group.   
There is no difference in caesarean section. Postpartum metabolic control values- HbA1c, FBG 
and 2h BG after 75g OGTT- are higher in overweight/obese women. 
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Table 7. Overweight and obesity as a predictor factor 
Outcome  BMI <25kg/m2 
(n=338) 
BMI ≥ 25kg/m2 
(n=335) 
Beta (95 % CI) or  
OR* (95% CI) 
p-value 
HbA1c RDV1a 
Mean (SD)  
5.39 (0.37) 5.55 (0.43) 0.15 (0.09-0.21) <0.0001 
HbA1c end of pregnancy  
Mean (SD)b 
5.52 (0.38) 5.59 (0.41) 0.077 (-0.02-0.18) 0.138 
Need for treatment, 
yes/no, N (%) 
152/149  
(50.5/49.5) 
197/111 
(63.96/36.04) 
1.74* (1.26-2.40) 0.001 
Cesarean vs vaginal 
N (%)  
110/149 
(42.5/57.5) 
110/154 
(58.33/41.67) 
0.97* (0.68-1.37) 0.852 
HbA1c ppc 
Mean (SD) 
5.34 (0.37) 5.44(0.37) 0.09 (0.04-0.15) 0.002 
FBG ppc 
Mean (SD)  
4.89 (0.51) 5.16 (0.59) 0.27 (0.18-0.36) <0.0001 
2h BG ppc  
Mean (SD) 
5.44 (1.59) 5.76 (1.75) 0.33 (0.06-0.59) 0.017 
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
 
Pregnancy and maternal adverse metabolic outcomes regarding obesity as a predictive factor 
are reported in Table 8. HbA1c levels during pregnancy are significantly higher in the group of 
obese women than in the nonobese group, both at the first GDM visit and at the end of 
pregnancy. These women also present a 67% more frequent need to treat.  
 
Table 8. Obesity as a predictor factor 
Outcome BMI <30kg/m2  
(n= 525) 
BMI ≥ 30kg/m2  
(n=148)  
Beta (95 % CI) or 
OR* (95% CI) 
p-value 
HbA1c RDV1a 
Mean (SD)  
5.44 (0.39) 5.59 (0.46) 0.15 (0.07-0.22) <0.0001 
HbA1c end of 
pregnancy  
Mean (SD)b 
5.54 (0.37) 5.66 (0.48) 0.13 (0.01-0.25) 0.045 
Need for treatment, 
yes/no, N (%) 
257/214 
(54.6/45.4) 
92/46 
(66.7/33.3) 
1.67* (1.12-2.48) 0.012 
Cesarean vs vaginal 
N (%)  
167/241 
(40.9/59.1) 
53/62 
(46.1/53.9) 
1.23* (0.81-1.87) 0.323 
HbA1c ppc 
Mean (SD) 
5.37 (0.37) 5.47 (0.38) 0.11 (0.04-0.18) 0.003 
FBG ppc 
Mean (SD)  
4.99 (0.57) 5.16 (0.54) 0.17 (0.07-0.28) 0.002 
2h BG ppc  
Mean (SD) 
5.58 (1.71) 5.69 (1.56) 0.11 (-0.21-0.44) 0.496 
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
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The is no difference in the rate of caesarean section. However, HbA1c and FBG after the 75g 
OGTT values were significantly higher in the group of obese women. 
 
Pregnancy and maternal adverse metabolic outcomes regarding all risk factors together 
according to ADA 2017, using overweight as a risk factor, are reported in Table 9. HbA1c levels 
at first GDM visit are significantly higher in the group with the risk factors than in the group 
without, but not at the end of the pregnancy. Pharmacologic treatment is also initiated 87% 
more frequently in this group. 
 
Table 9. All RF together as predictive factors according to ADA 2017 (using overweight as a RF) 
Outcome  No RF_25 
(n=156) 
All RF_25  
(n=517) 
Beta (95 % CI) or  
OR* (95% CI) 
p-value 
HbA1c RDV1a 
Mean (SD)  
5.38 (0.35) 5.50 (0.42) 0.14 (0.06-0.22) 0.001 
HbA1c end of 
pregnancy  
Mean (SD)b 
5.51 (0.36) 5.58 (0.41) 0.08 (-0.04-0.2) 0.196 
Need for treatment, 
yes/no, N (%) 
69/76 
(47.59/52.41) 
293/191 
(60.54/39.46) 
1.87* (1.26-2.79) 0.002 
Cesarean vs vaginal 
N (%)  
57/78  
(42.22/57.78) 
171/240 
(41.61/58.39) 
0.93* (0.61- 1.42) 0.743 
HbA1c ppc 
Mean (SD) 
5.32 (0.37) 5.41 (0.37) 0.11 (0.03-0.18) 0.004 
FBG ppc 
Mean (SD)  
4.85 (0.44) 5.08 (0.59) 0.27 (0.16-0.38) <0.0001 
2h BG ppc  
Mean (SD) 
5.31 (1.63) 5.71 (1.72) 0.51 (0.18-0.84) 0.002 
This table compares the outcome in groups without and with at least one risk factor (RF) according to the criteria 
from ADA 2017 (with BMI ≥25 kg/m2).  
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
There is no difference in the rate of caesarean sections. HbA1c and 75g OGTT values (FBG, 2h- 
glucose) were significantly higher in the group with risk factors. 
 
Pregnancy and maternal adverse metabolic outcomes regarding all risk factors together 
according to NICE 2015, using obesity as a risk factor, are reported in Table 10.  
HbA1c levels, both at first GDM visit and at the end of the pregnancy, were significantly with 
risk factors than the group without. Medical glucose treatment is 66% more frequent in the 
former group.  
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Table 10. All RF as predictive factors according to NICE 2015 (using obesity as RF) 
Outcome during 
pregnancy 
No RF_30 
(n=215) 
All RF_30 
(n=458) 
Beta (95 % CI) or  
OR* (95% CI) 
p-value 
HbA1c RDV1a 
Mean (SD)  
5.39 (0.35)  
 
5.51 (0.43) 
 
0.14 (0.07-0.21) <0.0001 
HbA1c end of 
pregnancy b 
Mean (SD) 
5.49 (0.34) 
 
5.60 (0.42) 
 
0.11 (0.01-0.22) 0.040 
Need for treatment, 
yes/no, N (%) 
98/98 
(50/50) 
264/169 
(60.97/39.03) 
1.66* (1.16-2.37) 0.005 
Cesarean vs vaginal 
N (%)  
72/109 
(39.78/60.22) 
156/209 
(42.74/57.26) 
1.12 *(0.76-1.64) 0.560 
HbA1c ppc 
Mean (SD) 
5.32 (0.35) 
 
5.42 (0.38) 0.11 (0.04-0.17) 0.001 
FBG ppc 
Mean (SD)  
4.91 (0.46) 
 
5.08 (0.60) 
 
0.19 (0.09-0.29) <0.0001 
2h BG ppc  
Mean (SD) 
5.37 (1.57) 
 
5.74 (1.76) 
 
0.44 (0.14-0.73) 0.003 
This table compares the outcome in groups without and with at least one risk factor (RF) according to the criteria 
from NICE 2015 (with BMI ≥30 kg/m2).  
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
 
Once again, there is no difference in the rate of caesarean sections. The women in the group 
with risk factors have higher postpartum metabolic control values, both HbA1c and 75g OGTT 
(FBG and 2h BG). 
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A summary of pregnancy and maternal adverse metabolic outcomes and all the risk factors 
assessed are presented in Table 11. 
  
Table 11. Summary of results 
Predictive factors 
 
 
 
Outcomes  
GDM 
history  
First 
degree 
relative 
with 
T2DM  
High risk 
ethnicity  
Overweight 
and obese 
Obese  All 
RF_251 
All 
RF_302 
HbA1c RDV1a + + + + + + + 
HbA1c end of 
pregnancyb 
- + - - + - + 
Need for 
treatment 
+ + + + + + + 
Caesarean vs 
vaginal  
- - - - - - - 
HbA1c ppc + - + + + + + 
FBG ppc + - + + + + + 
2h BG ppc + + + + - + + 
1. comparing the outcome in groups without and with at least one risk factor (RF) according to the criteria from 
ADA 2017 (with BMI ≥25 kg/m2) 
2. comparing the outcome in groups without and with at least one risk factor (RF) according to the criteria from 
NICE 2015 (with BMI ≥30 kg/m2) 
a. refers to HbA1c measured at the first GDM visit 
b. refers to HbA1c measured at the end of pregnancy  
c. denotes 6-8 weeks postpartum during a 75 g oral glucose tolerance test 
 
Discussion  
 
GDM is a common condition with rising prevalence associated with higher maternal and 
neonatal complication. GDM is also responsible for higher lifetime morbidity for both the child 
and the mother. Diagnosis and adequate treatment of this condition is now part of the usual 
care (20-24). Debates are still ongoing regarding the optimal screening procedure; shall we 
screen all women or a selected group of pregnant women. The IADPSG consensus panel serves 
“as the basis for internationally endorsed criteria for the diagnosis and classification of 
diabetes in pregnancy”(13). This panel recommends universal screening using a 75g OGTT at 
24-28 weeks of gestational age. However, as a result, the total incidence of GDM and therefore 
immediate therapeutic cost will rise. Financial constraints and public health priorities are 
important factors in the decision making. Cost effectiveness and the financial impact of the 
2011 IADPSG recommendation have been largely discussed  (25-26-2).   
 
The present study was performed to investigate the impact of the presence - or lack - of risk 
factors on maternal outcomes in pregnancies complicated with GDM, during pregnancy and 
after delivery.  Following the ADA or NICE recommendation, women without risk factor make 
up, about 23% or 32% respectively, of the study population, which is rather low. Our findings, 
regarding pregnancy outcomes, are that regardless of the type of risk factor, women with risk 
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factor had higher HbA1c levels at the first appointment at the GDM clinic. For some risk 
factors, namely first-degree relatives with T2DM and obesity, HbA1c levels at the end of 
pregnancy were also higher. Women with RF were more likely to be pharmacologically treated 
and this, too, is seen for any of the risk factors. However, we found no significant difference 
in caesarean sections rates according to the presence of risk factor. Having a GDM history, a 
first degree relative with T2DM, being of a high-risk ethnicity or being obese were associated 
with adverse postpartum metabolic outcome.  
Certain differences during pregnancy between women with and without RF were found in all 
situations, regardless of the RF: These were HbA1c at the first GDM meeting and the need for 
medical treatment. That means that indeed women with RF come into the treatment centre 
with a riskier metabolic profile. Importantly, 48% of women without any risk factor according 
to the ADA criteria still needed medical treatment. This argues more for a need for universal 
screening. 
 
Surprisingly, none of the risk factor studied in this paper, demonstrated an association 
between the mode of delivery (c-section) and the analysed risk factor (27). This can be 
explained as all women, regardless of the presence or absence of their RF, have the same goals 
regarding weight gain, glucose thresholds etc and that women with RF have more frequently 
medical treatment in order to improve their outcomes. This may thus have diluted the 
difference of C-section which is rather a hopeful finding. 
 
The postpartum evaluations are performed 6-8 weeks after delivery, thus 6-8 weeks after the 
stop of all glucose self-control and medical treatment and clinical follow-up. At this moment, 
almost all situations show that women with RF have higher metabolic values and thus are at 
higher risk. This concerns HbA1c, FBG and 2h values after the 75g OGTT. This is important, as 
1/3 of women have prediabetes at 1-year postpartum and the values in the early postpartum 
phase are predictive for the 1-year postpartum values (28). This might implicate that women 
with RF should need a more intense follow-up and lifestyle intervention in the post-partum 
phase which is not always easy to implement. 
 
The strength of our study includes the quality outcome data extracted from medical records 
and the representativity of the population. As for limitations, we performed multiple testing 
and did not adjust for this. This would have been more complicated in the setting of a master 
thesis. Similarly, we did not adjust for confounder variables such as age, gestational age, 
previous parity etc. Other limitations are that we included only four risk factors of the known 
risk factors for diabetes. Therefore, we are unable to capture the overall impact of GDM, a 
multifactorial and complex disease. This choice was made after reviewing literature and 
singling out the most important risk factors (25-26-27-29). Ethnicity and BMI are among RF 
with strong impact on pregnancy outcomes (25). History of GDM and history of first-degree 
relatives with T2DM are one of the most important risk factors for developing GDM. Other 
reasons to choose these RF were their prevalence, for example for overweight and obesity 
and the feasibility to define these risk factors clearly and precisely in routine clinical care. This 
was for example more difficult for physical inactivity. Studying the relationship between risk 
factors and outcomes in a clinical setting where all women are treated with glucose self-
control, lifestyle changes and medical treatment as needed, also implies that certain outcomes 
will be adapted, or the impact diluted. Performing a randomized trial were in one arm all 
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women are screened and treated and in the other only women with risk factors could give us 
a clearer answer but would be challenging to perform.  
 
Conclusion  
 
Women with a history of GDM and with first degree relative with type 2 diabetes mellitus, 
women of high-risk ethnicity and overweight/obese women have more frequent adverse 
pregnancy and maternal metabolic outcomes during and specifically after pregnancy. 
Importantly, although lower than for women with RF, the need for medical treatment is very 
high in women without any RF. Surprisingly none of these risk factors are associated with an 
increase of caesarean section in pregnancies complicated with GDM in the setting of routine 
clinical care (30) and few are associated with a difference of metabolic control at the end of 
pregnancy.  This could mean that current clinical care can abolish some of the higher risk 
during pregnancy such as differences in metabolic control at the end of pregnancy and the 
need for caesarean section, but not differences in the postpartum period. This could implicate 
that women with RF should have a more intense follow-up and intervention in the postpartum 
period. It is worth recognising RF at diagnosis and throughout pregnancy and therefore 
customise care management in order to prevent adverse outcomes.  
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